97175 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
A PREDICTIVE SCORE OF CANCER IMMUNOTHERAPY OUTCOME BASED ON ECOLOGICAL ANALYSIS OF GUT MICROBIOTA
#2ANTI-WT1/HLA ANTIBODIES AND USES THEREOF
#3MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIES
#4IL-2 PROCYTOKINE ANTIBODY FUSION PROTEINS
#5RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGING
#6DUAL SPECIFICITY ANTIBODIES TO HUMAN PD-L1 AND PD-L2 AND METHODS OF USE THEREFOR
#7NANOBODIES FOR CANCER THERAPY
#8CEACAM5 ANTIBODY-DRUG CONJUGATE FORMULATION
#9ANTI-LRRC15 ANTIBODIES AND USES THEREOF
#10haNK Cetuximab Combinations And Methods
#11METHODS, DEVICES, AND SYSTEMS FOR PREDICTING TREATMENT RESPONSIVENESS OF CLEAR CELL RENAL CELL CARCINOMA PATIENTS
#12ACTIVATION OF RESIDENT MEMORY T CELLS FOR THE TREATMENT OF CANCER
#13INTRATUMORALLY INJECTED YEAST VACCINE
#14GDF-15 AS A DIAGNOSTIC MARKER TO PREDICT THE CLINICAL OUTCOME OF A TREATMENT WITH IMMUNE CHECKPOINT BLOCKERS
#15ANTI-CANCER TGFB2 AGENTS WITH IMMUNOTHERAPEUTICS
#16IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#17STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER
#18PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF
#19ACTIVATABLE BISPECIFIC ANTI-CD89 AND ANTI-PD-L1 PROTEINS AND USES THEREOF
#20BISPECIFIC ANTIBODIES THAT BIND PD-L1 AND CD28
#21ANTI-IL-2 ANTIBODY COMBINATIONS AND METHODS OF USE THEREOF
#22ANTIBODIES BINDING B7-H3 AND USES THEREOF
#23ANTI-CD3 ANTIBODY AND USE THEREOF
#24CD3-TARGETING ANTIBODY AND USE THEREOF
#25Antibodies Binding to ILT4
#26VEGETATION MANAGEMENT SYSTEM AND VEGETATION MANAGEMENT METHOD
#27CLEC9A BINDING AGENTS
#28THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF ANTI-CANCER AGENT(S) AND IMMUNE CHECKPOINT INHIBITOR(S)
#29ANTI-B7H3 ANTIBODIES AND METHODS OF USE
#30Methods of Performing Boron Neutron Capture Therapy (BNCT) in Combination with Immune Checkpoint Inhibitors to Enhance BNCT and the Anti-tumor effects of Immune Check Point Inhibitors as well as the Abscopal Effect Induced by Radiation Therapy and Methods Thereof
#31PHARMACEUTICAL COMPOSITION COMPRISING ANTI-PD-L1 ANTIBODY USED IN COMBINATION WITH ANTI-VEGF ANTIBODY AND PACLITAXEL (as amended)
#32BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF
#33METHODS AND COMPOSITIONS FOR TREATING CANCER
#34PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY
#35T-Cell Modulatory Polypeptides and Methods of Use Thereof
#36LAG-3 ANTAGONIST THERAPY FOR MELANOMA
#37MODULATION OF DENDRITIC CELL LINEAGES
#38IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE
#39IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE
#40USE OF ONCOLYTIC VIRUSES, ALONE OR IN COMBINATION WITH A CHECKPOINT INHIBITOR, FOR THE TREATMENT OF CANCER
#41TREATING AND PREVENTING MICROBIAL INFECTIONS
#42TREATING AND PREVENTING MICROBIAL INFECTIONS
#43Cµ4 REGION FOR PAIRING HEAVY AND LIGHT CHAINS IN MULTI-SPECIFIC ANTIBODIES
#44TREATMENT AND PREVENTION OF CANCER USING VISTA ANTIGEN-BINDING MOLECULES
#45CRYSTALLISATION OF A PROTEIN CAPABLE OF CRYSTALLIZING UNDER SALTING-IN CONDITIONS USING MULTIPLE PROTEIN FEEDS
#46Antibody Compositions and Methods of Use Thereof
#47METHODS AND COMPOSITIONS FOR CLASSIFYING AND TREATING BLADDER CANCER
#48B7H3/PDL1 BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF
#49COMPOSITION FOR SYSTEMIC ANTICANCER TREATMENT IN LOCALIZED RADIOTHERAPY
#50Methods for Treating Cancer Using a Stat3 Double-Stranded, Cyclic Oligonucleotide Decoy
#51BISPECIFIC ANTIBODIES AND USES THEREOF
#52ANTI-B7H3 ANTIBODIES AND METHODS OF USE
#53MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOF
#54Carrier-PD-L1 Binding Agent Compositions for Treating Cancers
#55METHODS OF TREATING CANCER WITH AN ANTI-PD-L1 ANTIBODY
#56ANTI-PDL1 ANTIBODY AND USE THEREOF
#57ANTI-VISTA CONSTRUCTS AND USES THEREOF
#58Regulatable Cell Surface Receptors and Related Compositions and Methods
#59ONCOLYTIC VIRUS EXPRESSING AN IMMUNE CELL ENGAGER FOR TUMOR TARGETING
#60ENHANCED IMMUNE CHECKPOINT BLOCKADES FORMULATION FOR IMAGE GUIDED LOCAL IMMUNOTHERAPY
#61TIGIT ANTIBODIES, ENCODING NUCLEIC ACIDS AND METHODS OF USING SAID ANTIBODIES IN VIVO
#62PILRA Antibodies and Methods of Use Thereof
#63ANTI-GDF15 ANTIBODY FOR NEOADJUVANT THERAPY OF CANCER
#64CD8 BINDING AGENTS
#65METHODS FOR TREATING CANCER
#66METHODS OF USING PD-L1 EXPRESSION IN TREATMENT DECISIONS FOR CANCER THERAPY
#67Mutated Influenza Virus, Pharmaceutical Composition, and Use
#68IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#69ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#70DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
#71THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#72BISPECIFIC ANTIBODY AND USE THEREOF
#73ANTI-IL-27 ANTIBODIES AND USES THEREOF
#74ANTI-GDF15 ANTIBODY AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCER
#75TREATING AND PREVENTING MICROBIAL INFECTIONS
#76TETRAVALENT MULTISPECIFIC ANTIBODIES
#77ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS
#78ANTI-PD-L1 MULTIPARATOPIC ANTIBODY CONSTRUCTS AND USES THEREOF
#79MULTISPECIFIC ANTIBODY WITH COMBINATION THERAPY FOR IMMUNO-ONCOLOGY
#80ANTI-CTLA4 ANTIBODIES FOR TREATMENT OF KRAS MUTANT CANCERS
#81CYTOKINE FUSION PROTEIN CAPABLE OF CONDITIONAL RELEASE AND ACTIVATION, AND PREPARATION AND USE THEREOF
#82METHODS OF ADMINISTERING NATURAL KILLER CELLS COMPRISING AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) CHIMERIC ANTIGEN RECEPTOR (CAR)
#83INTRALESIONAL ADMINISTRATION OF PD-1 INHIBITORS FOR TREATING SKIN CANCER
#84ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
#85ENHANCED FUSION POLYPEPTIDE FOR IMMUNOTHERAPY
#86AN HDAC INHIBITOR FOR TREATING CANCER WITH A MODIFIED STK11 ACTIVITY OR EXPRESSION
#87BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#88ANTI-PODXL ANTIBODIES FOR INHIBITING CTC CLUSTERING
#89VISTA-BINDING ANTIBODIES AND METHODS OF USE THEREOF
#90METHOD FOR PREPARING ENHANCED CAR-T-CELLS BASED ON INTERFERING OR KNOCKING OUT HUMAN PCSK9 GENE AND APPLICATION THEREOF
#91METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#92METHODS FOR TREATING CANCER INCLUDING GLATIRAMER ACETATE AND IMMUNE CHECKPOINT INHIBITORS
#93PEPTIDE LINKERS FOR CONSTRUCTION AND REDUCING AGGREGATION OF FUSION POLYPEPTIDES COMPRISING SUCH
#94Implantable Device for Sustained Release of a Macromolecular Drug Compound
#95ANTIBODIES SPECIFICALLY RECOGNIZING PROGRAMMED CELL DEATH1 LIGAND 1 AND USES THEREOF
#96ANTI-ROR1 ANTIBODY, BISPECIFIC ANTIBODY COMPRISING SAME, AND USES THEREOF
#97TXNIP INHIBITION TO ENHANCE ADOPTIVE IMMUNOTHERAPY
#98Methods and Compositions For Targeting Retinoic Acid For Solid Tumor Immunotherapy
#99Anti-B7-H3 Antibody and Methods of Use Thereof
#100USE OF ANTI-MARCO ANTIBODY WITH A CHECKPOINT BLOCKADE ANTIBODY FOR THE TREATMENT OF CANCER
#101Engineered PD-L1-Targeting Gamma Delta T Cell Receptors
#102Programmable Bacteria for the Treatment of Cancer
#103ANTIBODIES AGAINST SIGNAL-REGULATORY PROTEIN ALPHA AND METHODS OF USE
#104DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
#105Methods of Treating PD-L1 Expressing Cancer
#106MULTISPECIFIC ANTIBODY AND PREPARATION METHOD AND USE THEREOF
#107NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF
#108COMBINATION THERAPY FOR LUNG CANCER
#109B7-H3 TARGETED SINGLE-DOMAIN ANTIBODY, CHIMERIC ANTIGEN RECEPTOR MOLECULE, CHIMERIC ANTIGEN RECDPTOR CELL, AND USE THEREOF IN PREPARATION OF DRUGS FOR TREATING NASOPHARYNGRAL CARCINOMA
#110Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer
#111ANTI-PDL1 ANTIBODY FORMULATIONS
#112COMPOSITION FOR ELICITING INFECTIOUS IMMUNOLOGICAL TOLERANCE
#113MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION
#114THERANOSTIC FOR TREATING CANCER
#115ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#116B7H3 BINDERS
#117Antibody Variable Domains And Antibodies Having Decreased Immunogenicity
#118COMPOSITIONS CONTAINING ACTIVATABLE ANTIBODIES
#119BISPECIFIC ANTIBODY BINDING EGFR AND B7-H3
#120RECOMBINANT ANTIBODIES, CHIMERIC ANTIGEN RECEPTORS, AND USES THEREOF IN TREATING CANCERS
#121HUMANIZED ANTI-CD28 ANTIBODY AND BISPECIFIC ANTIBODY THEREOF WITH ANTI-CD40 ANTIBODY
#122ANTI-CD40 ANTIBODY, ANTI-PD-L1×CD40 BISPECIFIC ANTIBODY, AND USE THEREOF
#123CHIMERIC CHECKPOINT RECEPTOR FOR THE USE IN TREATMENT OF MALIGNANT B-CELL DISEASES
#124CBL-B INHIBITORS AND ANTI-PD1/ANTI-PD-L1 FOR USE IN THE TREATMENT OF CANCER
#125NUCLEI-BASED DIGITAL PATHOLOGY SYSTEMS AND METHODS
#126USE of Antibody Mutation FOR Therapeutic Antibody Drug
#127MULTIFUNCTIONAL RECOMBINANT ANTIBODY, PREPARATION METHOD AND USE THEREOF
#128Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)
#129PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY-DRUG CONJUGATE AND USE THEREOF
#130METHODS OF TREATING PANCREATIC CANCER WITH A PD-1 AXIS BINDING ANTAGONIST AND AN RNA VACCINE
#131ANTITUMOR IMMUNE CHECKPOINT REGULATOR ANTAGONISTS
#132PD-1 AND PD-L1 BINDING AGENTS
#133METHODS OF TREATING HER2-POSITIVE CANCER
#134FORMULATIONS FOR ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES
#135ANTI- SIGLEC-15 BINDING MOLECULES AND METHODS OF USE
#136ANTI-SIGLEC15 ANTIBODIES AND USES THEREOF
#137ANTI-VISTA ANTIBODIES AND FRAGMENTS
#138ANTI-HLA-G ANTIBODIES, COMPOSITIONS COMPRISING ANTI-HLA-G ANTIBODIES AND METHODS OF USING ANTI-HLA-G ANTIBODIES
#139MULTISPECIFIC BINDING AGENTS THAT TARGET B7H3 AND GD2 AND USES THEREOF
#140ANTI-BTN3A ANTIBODIES FOR USE IN METHODS OF TREATING GASTRO-INTESTINAL INFLAMMATORY DISORDERS
#141POLYINOSINIC- POLYCYTIDYLIC ACID COMPOSITIONS AND METHODS OF MAKING SAME
#142Improved Therapeutic Index of Anti-Immune Checkpoint Inhibitors Using Combination Therapy Comprising A PHY906 Extract, A Scutellaria baicalensis Georgi (S) Extract or A Compound From Such Extracts
#143COMBINATION THERAPIES COMPRISING FUNCTIONAL COMPONENTS OF PD-1 SWITCH RECEPTOR AND FAS DOMINANT NEGATIVE RECEPTOR
#144ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137
#145OX40 Binding Proteins for Cancer Regulation
#146ANTI-PD-L1 ANTIBODIES AND METHODS OF USE THEREOF
#147ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#148ANTI-PD-L1 SINGLE-DOMAIN ANTIBODY AND DERIVATIVES AND USE THEREOF
#149ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
#150CATEQUENTINIB (ANLOTINIB) IN SEQUENTIAL COMBINATION WITH IMMUNOTHERAPY FOR USE IN THE TREATMENT OF CANCER
#151GENETICALLY MODIFIED NK-92 CELL LINE
#152COMBINATION THERAPY FOR TREATMENT OF CANCER COMPRISING ANTI-PD-L1 AND ANTI-CD73 ANTIBODIES
#153ANTIBODIES
#154ANTI-PD-L1 MONOCLONAL ANTIBODIES AND FUSION PROTEINS WITH INTERLEUKIN-15, INTERLEUKIN-15 RECEPTOR ALPHA, OR INTERLEUKIN-2
#155METHODS OF TREATING TUMOR
#156USES OF ANTI-ICOS ANTIBODIES
#157BISPECIFIC ANTIBODY COMPRISING A HETERODIMER BASED ON MHC PROTEINS
#158TREATMENT
#159MULTIFUNCTIONAL MOLECULES THAT BIND TO T CELL RELATED CANCER CELLS AND USES THEREOF
#160ACTIVATABLE DUAL-ANCHORED MASKED MOLECULES AND METHODS OF USE THEREOF
#161ANTIGEN-RECOGNIZING RECEPTORS TARGETING B7-H3 AND USES THEREOF
#162IMMUNE CHECKPOINT INHIBITOR COMBINATIONS
#163NOVEL POLYINOSINIC- POLYCYTIDYLIC ACID COMPOSITIONS
#164ANTI-PDL1 ANTIBODIES, MULTISPECIFIC ANTIBODIES AND METHODS OF USE
#165BISPECIFIC ANTIBODY COMBINATION AND USE THEREOF
#166ANTIBODIES AGAINST TIM3 AND USES THEREOF
#167BISPECIFIC ANTIBODY TARGETING SIRP-alpha AND PD-L1 OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE
#168ANTI-SIGLEC15 ANTIBODY AND USE THEREOF
#169ANTI-TIGIT ANTIBODIES AND METHODS OF USE
#170COMBINATION THERAPY OF CLAUDIN 18.2 ANTAGONIST AND PD-1/PD-L1 AXIS INHIBITOR
#171ICOS-L VARIANT WITH ENHANCED BINDING AFFINITY FOR ICOS
#172ENGINEERED INTERLEUKIN-2 RECEPTOR BETA REDUCED-BINDING AGONIST
#173ANTIBODY-DRUG CONJUGATE CONTAINING PROTEIN DEGRADATION AGENT BIOACTIVE COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF
#174GLYCOPEPTIDE MEDIATED T CELL IMMUNITY AND ANTI-TUMOR EFFICACY IN CANCER
#175ANTI-PDL1 ANTIBODIES AND METHODS OF USE
#176CHIMERIC ANTIGEN RECEPTORS TARGETING B7-H3 (CD276) AND ASSOCIATED METHODS
#177ANTI-LY6H ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#178NOVEL ANTI-PD-L1 ANTIBODIES
#179Anti-B7H3 antibody and Uses thereof
#180ANTI-B7-H3 ANTIBODIES AND USES THEREOF
#181TREATMENT AND PREVENTION OF CANCER USING VISTA ANTIGEN-BINDING MOLECULES
#182NOVEL CYTOKINE-BASED THERAPIES AND METHODS
#183Primary NK CAR Constructs And Methods
#184B7H3 ANTIBODY DRUG CONJUGATES
#185COMPOSITIONS OF LIPID NANOPARTICLES FOR PLASMID DNA DELIVERY TO THE LIVER AND METHODS FOR PREPARING THE SAME
#186ANTITUMOR BACTERIAL STRAIN, AND COMPOSITION AND METHOD USING SAME
#187Germinal Center Response to Engineered Bacteria Promotes Bladder Cancer Immunotherapy
#188THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#189BIOMARKERS FOR PREDICTING TUMOR RESPONSE TO AND TOXICITY OF IMMUNOTHERAPY
#190Treatment for colorectal cancer using immune checkpoint inhibitors
#191ANTI-GDF15 ANTIBODY USED IN A COMBINATION TREATMENT OF SPECIFIC PATIENT GROUPS AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCER
#192NKG2D EXPRESSING CAR-T CELLS
#193ANTI-CD16A ANTIBODY AND APPLICATION THEREOF
#194Anti-B7-H4 Antibodies and Immunoconjugates
#195COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#196ENGINEERED CELLS, T CELL IMMUNE MODULATING ANTIBODIES AND METHODS FOR USING THE SAME
#197METHODS OF TREATING LOCALLY ADVANCED OR METASTATIC BREAST CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#198HYBRID TUMOR/CANCER THERAPY BASED ON TARGETING THE RESOLUTION OF OR INDUCING TRANSCRIPTION-REPLICATION CONFLICTS (TRCS)
#199SELECTIVE K-RAS INHIBITORS FOR THE ENHANCEMENT OF ADOPTIVE IMMUNOTHERAPIES
#200Anti-CTLA-4 Binding Proteins and Methods of Use Thereof
#201USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING CANCERS
#202CHIMERIC ANTIGEN RECEPTOR AGAINST PROGRAMMED DEATH LIGAND 1 (PD-L1) AND APPLICATION THEREOF
#203CHIMERIC ANTIGEN RECEPTOR AGAINST PROGRAMMED DEATH LIGAND 1 (PD-L1) AND APPLICATION THEREOF
#204PHARMACEUTICAL COMBINATION AND USE THEREOF
#205ANTI-GDF15 ANTIBODY AND A DOSAGE REGIMEN FOR THE TREATMENT OF CANCER
#206TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST
#207SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER
#208CANINE PD-L1 ANTIBODY, ANTIGEN BINDING FRAGMENTS THEREOF, AND METHODS OF USE THEREOF
#209ANTI-PD-L1 ANTIBODY AND USE THEREOF
#210MULTIFUNCTIONAL BISPECIFIC FUSION POLYPEPTIDE
#211SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE
#212A GROUP OF B7H3 MONOCLONAL ANTIBODIES AND MEDICAL USE THEREOF
#213CAR CONSTRUCTS AND METHODS OF TREATMENT
#214Combination Of Proteotypic Peptides For The Detection Of Proteins In The Pd-L1 Axis
#215ANTIBODIES FOR T-CELL ACTIVATION
#216ANTIBODY MOLECULES
#217HHLA2 BINDING AGENTS WITH NOVEL ACTIVITY
#218CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
#219MULTISPECIFIC ANTIBODIES AND USES THEREOF
#220CANCER THERAPY TARGETING NKG2A
#221SCAFFOLD PROTEINS
#222PD-1/PD-L1 INHIBITORS
#223ANTI-HUMAN B7-H3 ANTIBODY AND APPLICATION THEREOF
#224CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
#225ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#226ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF
#227AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF
#228IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#229IL-15-BASED MOLECULES AND METHODS OF USE THEREOF
#230METHODS TO IMPROVE STABILITY OF VIRUS TRANSDUCTION OF y8 T CELLS AND APPLICATIONS THEREOF
#231PHARMACEUTICAL FOR TREATING OR PREVENTING CANCER
#232CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
#233THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER
#234Anti-CD28 Antibodies and Methods of Use Thereof
#235IDENTIFICATION, IN VITRO AMPLIFICATION, AND APPLICATION METHOD OF MEMORY CD8 T CELLS SPECIFIC FOR TUMOR ANTIGEN
#236COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
#237DEGRADATION OF SURFACE PROTEINS USING DUAL BINDING AGENT
#238USES OF PDL1-BINDING PROTEINS
#239ANTI-C-C MOTIF CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES AND METHODS OF USE
#240PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLORECTAL CANCER, COMPRISING ESTROGEN AND ANTI-PD-L1 ANTIBODY
#241THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
#242ANTI-B7H3 ANTIBODIES AND METHODS OF USE
#243PD-L1 BINDING AFFIMERS
#244ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER
#245NEOADJUVANT CANCER TREATMENT
#246CD83 DUAL CAR T CELLS
#247COMBINATION THERAPIES BASED ON PD-1 INHIBITORS AND SIK3 INHIBITORS
#248TREATMENT OF CANCER USING A COMBINATION OF IMMUNOMODULATION AND CHECK POINT INHIBITORS
#249METHOD OF CHARACTERIZING TUMORS
#250ANTI-CD39 NANOBODY AND USES THEREOF
#251A FUSION POLYPEPTIDE AND ITS USE
#252METHODS AND COMPOSITIONS COMPRISING B7-H3 BINDING POLYPETIDES
#253PREDICTION OF CHEMOTHERAPY-FREE IMMUNOTHERAPY EFFECTIVENESS FOR PATIENTS WITH CANCERS
#254Methods and Products to Screen and Treat Glioblastoma Multiforme and Other Cancers, Including Breast Cancers, Using A Combination of PI3KINASE Inhibitors With Checkpoint Inhibitors
#255COMBINATION THERAPY INVOLVING ANTI-HLA-G ANTIBODIES AND ANTI-EGFR ANTIBODIES, ANTI-PD1 OR ANTI-PD-L1 ANTIBODIES, AND/OR ANTI-CD47
#256HUMAN ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF SPECIFIC AGAINST PD-L1 TO ENHANCE T-CELL FUNCTION
#257METHOD FOR PREDICTING PATIENT RESPONSE TO IMMUNOTHERAPY
#258ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
#259ANTIGEN-BINDING PROTEIN TARGETING PD-L1 AND CD40, PREPARATION THEREFOR, AND USE THEREOF
#260CD80 PROTEIN VARIANT AND CD80 FUSION PROTEIN
#261PHOTOACTIVATABLE NANOPARTICLES AND USES THEREOF AS AGENTS FOR IMMUNOTHERAPY COMBINATIONS
#262Antibody Compositions and Methods of Use Thereof
#263Methods and Compositions Comprising V beta 17 Bispecific T Cell Engagers and Bioengineered Virus Specific Lymphocytes
#264DEPLETING TUMOR-SPECIFIC TREGS
#265ANTI-HUMAN PD-Ll AND TLR7 DOUBLE-TARGETING NANOBODY CONJUGATE DRUG AND USE THEREOF IN RESISTING TUMOR
#266MULTISPECIFIC BINDING AGENTS AND USES THEREOF
#267RECOMBINANT ANTIBODY, IMMUNOCONJUGATE COMPRISING THE SAME, AND USES THEREOF IN TREATING CANCERS
#268METHODS OF TREATING CANCER
#269POOLING SIGNALING AND COSTIMULATORY DOMAINS IN B7H6 CHIMERIC ANTIGEN RECEPTOR
#270MCL1 INHIBITORS
#271NEW ANTIBODY-DRUG CONJUGATE AS WELL AS METHODS OF PRODUCTION AND USES THEREOF
#272IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE
#273METHOD FOR REDUCTION OF IMMUNE CHECKPOINT THERAPY RELATED ADVERSE EVENTS
#274METHODS AND COMPOSITIONS COMPRISING FUSION PROTEINS FOR IMPROVED IMMUNOTHERAPIES
#275TREATMENT OF ALVEOLAR SOFT PART SARCOMA (ASPS) WITH ATEZOLIZUMAB
#276ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN B7-H3
#277IL-18 POLYPEPTIDES FUSED TO IMMUNE CELL ANTIGEN SPECIFIC BINDING POLYPEPTIDES AND USES THEREOF
#278COMPOSITION FOR COMBI-THERAPY COMPRISING VEGF-GRAB AND PD-1 OR PD-L1 ANTAGONIST
#279PD-L1-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELL COMPRISING SAME
#280CAR-T CELL TARGETING B7-H3 AND APPLICATION THEREOF IN TREATMENT OF ACUTE MYELOID LEUKEMIA
#281THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER
#282RETROVIRAL-LIKE PARTICLE-REDUCED CHINESE HAMSTER OVARY PRODUCTION CELL LINES
#283COMBINING CD27 AGONISTS AND IMMUNE CHECKPOINT INHIBITION FOR IMMUNE STIMULATION
#284COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY TARGETING FLT3, PD-1, AND/OR PD-L1
#285Anti-SIRPa Antibodies and Methods of Use Thereof
#286ANTI PD-L2 ANTIBODY
#287ANTI-B7-H3 COMPOUNDS AND METHODS OF USE
#288ANTI-TREM1 ANTIBODIES AND RELATED METHODS
#289FOXP1-ABLATED CHIMERIC CELLS
#290NK/MONOCYTE ENGAGERS
#291COMBINATION THERAPY FOR COLORECTAL CARCINOMA
#292COMBINATION THERAPY OF LILRB ANTAGONIST AND PD-1/PD-L1 AXIS INHIBITOR
#293COMBINATION THERAPY FOR TREATMENT OF DISEASE
#294USE OF TGF-ALPHA POLYPEPTIDE OR ANTI-TGF-ALPHA ANTIBODIES FOR THE TREATMENT OF DISEASES AND DISORDERS
#295CHIMERIC ANTIGEN RECEPTOR TUMOR INFILTRATING LYMPHOCYTES
#296INTERLEUKIN-2/INTERLEUKIN-2 RECEPTOR ALPHA FUSION PROTEINS AND METHODS OF USE
#297RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS
#298COMBINATION TREATMENT FOR CANCER
#299METHODS OF CLASSIFYING RESPONSE TO IMMUNOTHERAPY FOR CANCER
#300DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES